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EVALUATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND 2 ANTIBODIES DETECTION
IN DRIED WHOLE BLOOD SPOTS (DBS) SAMPLES
Andréa Cauduro de CASTRO(1,3), Luiz Gustavo dos Anjos BORGES(4), Ricardo da Silva de SOUZA(4), Melina GRUDZINSKI(5) & Pedro Alves D’AZEVEDO(2)
SUMMARY
Human Immunodeficiency Vírus Type 1 and 2 antibodies detection was performed in 457 dried whole blood spots samples
(S&S 903). Q-Preven HIV 1+2 was the screening test used. The results were compared with the gold standard serum tests by
ELISA (Cobas Core e Axsym HIV1/2 gO) and imunofluorescence was the definitive confirmatory test.
The samples were obtained from the Hospital Nossa Senhora da Conceição in Porto Alegre, RS - Brazil, through whole blood
transfer to filter paper card and sent to Caxias do Sul, RS - Brazil where the tests were performed.
The dried whole blood spot stability was evaluated with two different panels. The first one was composed of five negative and
five positive samples stored at room temperature, 4 °C, -20 °C and -70 °C, while the second was composed of two negative and
three positive samples stored at 37 °C (humidity <50%). Each sample was screened every week for six weeks. These measurement
results didn’t show variation during the study period.
The detected sensibility was 100%, specificity was 99.6%, the positive predictive value was 99.5% and negative predictive
values were 100%. The results demonstrated high performance characteristics, opening a new perspective of dried whole blood
spot utilization in HIV screening diagnosis.
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INTRODUCTION
The UNAIDS and WHO estimated that 39.5 million [34.1 million
- 47.1 million] people worldwide were living with HIV in 2006. New
infections counted 4.3 million [3.6 million - 6.6 million] cases and 2.9
million [2.5 million - 3.5 million] lost their lives to AIDS. Global
estimatives indicates that the HIV incidence rate peaked in the late
1990s and stabilized subsequently, notwithstanding increasing in many
countries29.
 The utility of dried blood spots (DBS) for infectious disease testing
has been known for years18. The need for an expanded HIV diagnostic
coverage in Brazil is a challenging issue, due to Brazilian territorial
extension and expressive number of isolated populations. In this study
we evaluated the performance of HIV DBS testing, aiming towards
new alternatives to address this problem.
The ease of using dried blood samples led them to be collected
and stored under minimal conditions worldwide and without the need
for sophisticated equipment or training3,18,6,20,15.
Risks associated with shipping are minimized as DBS cannot leak
or be broken in transit and there is no requirement for carriage on dry
ice. Handling of potentially infected material is also reduced as the
need to centrifuge and separate sera from blood clots is eliminated25.
Dried blood spot can be used as an easy and inexpensive means for
the collection and storage of specimens under field conditions for the
diagnosis of HIV infection6.
The use of only a minute amount of whole peripheral blood allows
collection of blood by heel prick, requiring less skill and fewer supplies.
Once dry, blood samples on filter paper are no longer infectious and,
coupled with an absence of glass, reduce the risk to health care
workers5,19.
Standardized dried whole blood spot, as used in many other
infectious conditions, can be valuable resources on referencing samples
to technologically capable HIV diagnostic sites12. Initial doubts over
the sensitivity and the specificity of DBS based compared with
serological assays were dispelled by parallel testing of DBS and sera
which showed 99-100% concordance. Furthermore extensive studies
proved that concerns about the presence of haem in the eluate and
adverse storage, for example in tropical conditions, causing false
reactions were unfounded3,17,25. DBS has been used in large scale HIV
surveillance studies for over a decade16,26.
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OBJECTIVES
The aim of this study was to evaluate the efficiency of the HIV
antibodies detection in dried blood spot compared with the HIV
antibodies detection in serum with the ELISA and confirmatory tests,
according to Brazilian Ministry of Health algorithm (Portaria nº 59,
2003)8. Our specific objective was focused on HIV antibodies stability
in DBS stored under multiple conditions of time and temperature. These
results may contribute to the implement of HIV testing in remote areas
and the coverage of HIV screening during pregnancy.
MATERIALS AND METHODS
Samples: Along 2005 to 2006, patients from the Grupo Hospitalar
Conceição of Porto Alegre, RS, Brazil, tested for HIV were used.
Patients ages varied between two months and 78 years. 457 samples
were obtained. A dried whole blood spot panel was prepared by
transferring 50 µL of whole blood-EDTA specimens to collect card
S&S 903. Each collect card had five circles of about 13 mm of diameter.
These samples were dried at room laboratory temperature for four
hours prior to storage15,18,20.
The serum screening and confirmatory tests were performed in the
Immunology Unit of Hospital Conceição Laboratory of Porto Alegre,
as well as the whole blood samples transferred to the filter paper card.
The Laboratory got the American College of Pathology certification to
HIV diagnostic tests performed in this study.
The dried whole blood spot were sent, by mail, in zip lock plastic
bags with desiccant silica, to HIV/AIDS Research Laboratory of the
Caxias do Sul University and stored at room temperature, 4 °C, -20 °C
and -70 °C. DBS were screened at weeks one and six for HIV antibodies
by Q-Preven HIV 1+2. A sample group was stored at 37 °C and screened
at weeks one until five. All samples were sent without the knowledge
of serological status. The whole laboratory procedures followed the
Good Laboratory Practice and included all quality controls.
Statistical calculations:
true positiveSensibility = ———————————— x 100
true positive + false negative
true negativeSpecificity = ———————————— x 100
true negative + false positive
true positivePositive predictive value = ———————————— x 100
true positive + false positive
true negativeNegative predictive value = ———————————— x 100
true negative + false negative
Filter paper (Schleicher&Schuell, Keene, N.H.)
Filter paper grade 903 recommended by NCCLS (National
Committee on Clinical Laboratory Standards). Basis weight of 179 g/
m2, thickness of 0.52 mm, water absorbency of 4.44 g/100 cm2 and
wet strength of 3 psi.
SCREENING TESTS
HIV combi EIA (COBAS CORE-Roche, Germany)
This assay is a combination of a double antigen sandwich assay
(antibody detection module) comprising antigens from the env region
of HIV-1, HIV-2, HIV-1 Sub O and from the pol region of HIV-1 and a
monoclonal antibody sandwich assay (antigen detection module) of
four anti-p24 monoclonal antibodies. The anti-HIV/HIVAg combined
assay was applied to the Roche COBAS CORE System by using
recombinant antigens and anti-p24 monoclonal antibodies at the solid
phase (beads), as well as Digoxigenin labeled anti-p24 monoclonal
antibodies and peroxidase labeled antigens and anti-Digoxigenin. The
bead is incubated with TMB substrate and the intensity of the resulting
color is proportional to the amount of anti-HIV antibodies and HIV-1
p24 antigen detected in the specimen.
HIV 1 /2 gO (AXSYM-Abbott Laboratories, USA)
This test combines microparticle, fluorescent, and enzyme-linked
immunoassay technologies into an automated, random-access system.
Microparticles, the specimen dilution buffer, and the specimen are
incubated together in the first step. Serum antibodies are captured via
microparticle-bound recombinant proteins presenting key antigenic
portions of the representative of HIV type 1 group M, HIV-1 group O
or HIV-2. After incubation, AXSYM transfers microparticles bearing
immune complexes to a porous matrix and washes the matrix to remove
all unbound components or materials.
In the second step, biotinylated probes (recombinant antigens and
synthetic peptides) are added to microparticle-bound immune
complexes. After an incubation period, AXSYM washes the matrix
and removes unbound materials.
In the third step, biotinylated probes bound to the solid phase via
sandwich formation reacted with an anti-biotin rabbit antibody
complexed with alkaline phosphatase (conjugate). After another wash,
AXSYM detects the formation of immune complexes by automated
addition of 4-methylum-belliferyl phosphate, which is a fluorescent
substrate for the alkaline phosphatase. The flourescent signal is detected
and proportional to the amount of antibody contained in the serum
sample.
CONFIRMATORY TEST: IFI HIV-1 (Bio-Manguinhos, Brazil)
This test is an indirect immunofluorescence to anti-HIV-1
antibodies detection. Serum antibodies react with K37-3 cells, infected
by HIV-l, fixed on immunofluorescence microscope slides. Around
25-35% of cells own viral antigens suitable to be detected on the slide
surface. The reaction between the slide antigen and the sample antibody
is visualized after the fluorescein-isothiocyanate-conjugate human
immunoglobulin addition in a special immunofluorescence microscope
like brilliant stain cells.
FILTER PAPER TEST: Q-PREVEN HIV 1+2 – DBS (Brazil)
Enzyme immunoassay (EIA) Human Immunodeficiency Virus (HIV
1; HIV 2 and HIV 1 subtype O) antibodies detection in dried blood
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spot. A 4.7-mm punch from the DBS was eluted in 250 µL of buffer.
The eluate is dispensed in the appropriate well in the microplates with
recombinant proteins (p24, gp41 of HIV-1 and gp35 of HIV-2) and
HIV-1 subtype O synthetic peptide (gp41). In the first step, specific
antibodies are captured by specific antigens in the microplate. In the
second step, after aspiration and wash to remove all unbound materials,
the immune complexes are detected by addition of recombinant proteins
and synthetic peptides of HIV solution, conjugated with horseradish
peroxidase (HRPO). After aspiration and wash, the solid phase is
incubated with TMB substrate and the intensity of the resulting color
is proportional to the amount of anti-HIV antibodies in the sample that
can be read at 450 nm.
The project was approved by the Ethics Committee of the Hospital
Nossa Senhora da Conceição nº 042/05 and Ethics Committee of
Fundação Faculdade Federal de Ciências Médicas de Porto Alegre nº
142/06.
RESULTS
From 457 samples, 268 were negative and 189 were positive on
serologic tests. All 189 samples were also positive on DBS test. From
the 268 negative samples on serologic tests, 267 were negatives on
DBS test. The unmatched sample showed low optical density and triplet
testing revealed a final negative result (26N, Table 1).
The sensibility, specificity, negative predictive value (NPV) and
positivity predictive value (PPV) are present in Table 2.
The DBS stability on storage under temperature of 4 °C, -20 °C
and -70 °C and humidity <50% was 100%, with optical density (OD)
maintenance. Those stored under ambient temperature, mean 22.2 °C
(range from 12.1 to 27.2) and humidity mean 59.5% (range from 72%
to 45%) maintained their optical densities on week one. On week six,
one initially optical density low positive sample turned a negative result.
On week one, an increase on optical density of one negative (204)
sample was detected, but on week six, it became negative again, what
suggests a contamination problem (Tables 3 and 4).
Samples stored at 37 °C with air humidity maintained under 50%
showed stable results pattern on the first three weeks of analysis. After
the week four, the positive samples optical densities showed a decrease,
most of them crossing the positivity threshold on week five. The
negative samples did not show any variation (Table 5).
One positive sample with optical density (OD) 4.00 has been
processed with 10 consecutive dilutions until 1:1024. The result curve
is showed on Figure 1, the sample remaining positive until 1:256
dilution.
DISCUSSION
Our study showed adequate diagnostic performance of DBS testing
when compared to standard diagnostic procedures. The detected
sensibility was 100%, specificity was 99.6%, negative predictive value
(NPV) was 100% and the positive predictive value (PPV) was 99.5%
due to a false positive sample that failed to be confirmed on triplet
testing. This particular case was considered a contamination problem
of the initial testing. DBS stability was also accessed under various
environmental and timing conditions. The samples stored under low
temperatures (4 °C, -20 °C and -70 °C) revealed an excellent stability
until week six, maintaining the initial diagnostic result. One false
positive result was detected among room temperature (range at 22.2 °C)
Table 1
Results from sample panel tested on Dried Blood Spot versus serum samples
Samples Positives Negatives Total
on serum on serum
Positives on DBS 189 1 190
Negatives on DBS 0 267 267
Total 189 268 457
DBS dried blood spot
Table 3
Optical Density Ratio of the positive samples storaged in different temperature
conditions
Samples Week 1 OD Ratio Week 6 OD Ratio Storage (ºC)
110 13.65 15.27 -70
111 13.65 15.27 -70
112 13.65 11.72 -70
113 13.65 14.12 -70
114 5.10 4.00 -70
110 13.65 15.27 4
111 13.65 15.27 4
112 13.65 10.51 4
113 13.65 15.27 4
114 5.71 3.92 4
110 12.87 13.72 -20
111 13.65 15.27 -20
112 13.65 12.27 -20
113 13.65 15.27 -20
114 6.04 3.95 -20
110 13.65 15.27 Amb
111 13.65 13.68 Amb
112 13.15 8.83 Amb
113 13.25 15.27 Amb
114 6.45 0.95 Amb
OD = Optical Density; OD ratio = Sample Optical Density/cutoff; Cutoff =
Negative Control +0.1800.
Table 2
Diagnostic performance of Dried Blood Spot compared to standard diagnostic
procedure
Positive Negative Sensibility Specificity PPV NPV
Serum 189 268 100% 100% 100% 100%
DBS 190 267 100% 99.6% 99.5% 100%
PPV - positive predictive value; NPV - negative predictive value; DBS dried blood
spot.
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Weekly analysis of samples stored under 37 °C revealed reliable
positive results until the third week. Optical density decrease was
detected on the fourth and fifth weeks, however all samples had positive
status maintained.
In spite of the absence of borderline optical density, the dilution
sample performance proved good test sensibility.
Mother-to-child transmission (MTCT) is the dominant mode of
acquisition of HIV-1 among young children worldwide, and most of
them occur in late pregnancy, during labor or in the delivery. Postnatal
transmission through breastfeeding is estimated to contribute with one-
third to one-half of HIV-1 infections in children world-
wide2,9,11,13,14,21,22,23.
Table 5
Dried Blood Spot Sample performance storaged at 37 ºC for five weeks
Time of
Storage at Week 1 Weeks 2 Weeks 3 Weeks 4 Week 5s
37 oC
Samples OD OD Humidity OD OD Humidity OD OD Humidity OD OD Humidity OD OD Humidity
ratio ratio ratio ratio ratio
58630 0.162 0.62 < 50% 0.083 0.33 < 50% 0.091 0.36 < 50% 0.057 0.24 < 50% 0.059 0.25 < 50%
58579 0.082 0.31 < 50% 0.106 0.42 < 50% 0.08 0.31 < 50% 0.055 0.23 < 50% 0.057 0.24 < 50%
58948 4 15.27 < 50% 3.569 14.00 < 50% 3.297 12.93 < 50% 2.853 12.14 < 50% 1.329 5.66 < 50%
54138 2.304 8.79 < 50% 1.449 5.68 < 50% 1.555 6.10 < 50% 1.172 4.99 < 50% 0.941 4.00 < 50%
58938 3.205 12.23 < 50% 2.195 8.61 < 50% 1.497 5.87 < 50% 0.933 3.97 < 50% 0.453 1.93 < 50%
White 0.033 0.13 0.04 0.16 0.04 0.16 0.047 0.20 0.047 0.20
Positive 3.673 14.02 3.019 11.84 3.019 11.84 3.31 14.09 3.31 14.09
control
Negative 0.082 0.31 0.075 0.29 0.075 0.29 0.055 0.23 0.055 0.23
control
Cut-off 0.262 0.255 0.255 0.235 0.235
Test time 9/19/2006 10/2/2006 10/2/2006 10/13/2006 10/13/2006
OD = Optical Density; OD ratio = Sample Optical Density/cutoff; Cutoff = Negative Control +0.1800.
Table 4
Optical Density Ratio of the negative samples storaged in different temperature
conditions
Samples Week 1 OD Ratio Week 6 OD Ratio Storage (ºC)
204 0.47 0.42 -70
205 0.47 0.37 -70
206 0.73 0.35 -70
207 0.38 0.34 -70
208 0.43 0.47 -70
204 0.41 0.59 4
205 0.41 0.39 4
206 0.42 0.39 4
207 0.23 0.40 4
208 0.35 0.81 4
204 0.53 0.45 -20
205 0.49 0.34 -20
206 0.33 0.43 -20
207 0.38 0.35 -20
208 0.29 0.29 -20
204 1.88 0.55 Amb
205 0.48 0.48 Amb
206 0.39 0.62 Amb
207 0.41 0.71 Amb
208 0.33 0.48 Amb
OD = Optical Density; OD ratio = Sample Optical Density/cutoff; Cutoff =
Negative Control +0.1800.
stored samples on week one. The same sample showed a negative result
on week six.
Fig. 1 - Positive sample with consecutive dilutions procedures.
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Marked changes have occurred in mother-to-child transmission of
HIV in the United States and other developed countries since 1994,
when the Pediatric AIDS Clinical Trials Group (PACTG) protocol 076
showed that the administration of zidovudine to HIV-infected woman
during pregnancy and labor and to her newborn decreased the risk of
perinatal HIV transmission6,7,8,10,12,13. Perinatal HIV infection has
diminished to less than 2% after the implementation of
recommendations for universal prenatal HIV counseling and testing,
antiretroviral prophylaxis and elective cesarean delivery and avoidance
of breastfeeding1,7,9,21.
Brazilian AIDS incidence showed expressive changes since the early
80s28. The epidemiological pattern moved from a highly regional and
minority-specific profile to a country-wide epidemic in the 90s.
Regarding to HIV modes of transmission, heterosexual is the
predominant. This resulted in a rapid increase in HIV infection among
women, mostly of childbearing age. In parallel, there has been an
increase in the number of perinatally infected children24,28. In June
2000, 6,750 cases of AIDS in Brazilian children were reported. In spite
of the wide availability of specific antiretroviral therapy in Brazil, some
regions remain with poor diagnostic conditions, specially related to
pregnancy testing, screening strategies and confirmation procedures27.
These results may contribute with new strategies of HIV diagnostic
routines and logistics in our country. The possibility of room
temperature storage, mail shipping and laboratorial procedures
concentrated in reference sites indicates that a broader diagnostic
coverage may be offered maintaining the testing standard performances.
The impact on the prevention of MTCT ought to be particularly
beneficial as zidovudine is distributed by governmental health units,
but diagnostic availability remain the main obstacle to lowering
pediatric AIDS incidence.
RESUMO
Pesquisa de anticorpos contra o vírus da imunodeficiência
humana tipos 1 e 2 em amostras de sangue seco coletadas em
papel filtro
Foram realizados 457 testes para detectar anticorpos contra o Vírus
da Imunodeficiência Humana tipos 1 e 2, em amostras de sangue total
seco coletadas em papel filtro (S&S 903), com o teste de triagem Q-
Preven HIV 1+2, comparando-se com os resultados dos testes de
triagem no soro (Cobas Core e Axsym HIV1/2 gO), sendo a
imunofluorescência indireta o teste confirmatório.
As amostras foram obtidas no Hospital Conceição em Porto Alegre,
pela transferência de sangue total para cartão de papel filtro e
encaminhadas para Caxias do Sul para a realização dos testes.
Foi analisada a estabilidade da amostra em papel filtro com a
utilização de dois painéis: o primeiro com cinco amostras negativas e
cinco positivas armazenadas por seis semanas à temperatura ambiente,
4 °C, -20 °C e -70 °C; o segundo com duas negativas e três positivas
armazenadas por seis semanas com avaliações semanais a 37 °C
(umidade <50%). Os resultados de todas as amostras testadas foram
mantidos.
A sensibilidade foi de 100%, a especificidade de 99,6%, o valor
preditivo positivo de 99,5% e o valor preditivo negativo de 100%. O
excelente desempenho observado na análise da utilização de sangue
seco em papel filtro, abre uma nova perspectiva no diagnóstico da
infecção pelo HIV.
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